Abstract 3597: Direct Targeting of KRASG12X Mutant Cancers with RMC-6236, a First-in-class, RAS-selective, Orally Bioavailable, Tri-Complex RASMULTI(ON) InhibitorElena S. Koltun,Meghan A. Rice,W. Clay Gustafson,David Wilds,Jingjing Jiang,Bianca J. Lee,Zhengping Wang,Stephanie Chang,Mike Flagella,Yunming Mu,Nuntana Dinglasan,Nicole Nasholm,James W. Evans,Yingyun Wang,Kyle Seamon, Yang Liu,Cristina Blaj,John Knox,Rebecca Freilich,Elsa Quintana,Jim Cregg,Alun Bermingham,Adrian L. Gill,Jacqueline Am Smith,Mallika SinghCancer research（2022）引用 0|浏览21暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
